A Phase 1, Open-Label, Positron Emission Tomography Study in Healthy Adult Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of ASN51 Following a Single Oral Dose
Latest Information Update: 16 May 2025
At a glance
- Drugs ASN 51 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- Sponsors Asceneuron
Most Recent Events
- 03 May 2024 New trial record